LONDON - Shares in Antisoma plc plummeted 66 percent on news that its partner Novartis AG was stopping the Phase III trial of its lead product ASA404 in non-small-cell lung cancer (NSCLC), after an interim analysis showed the 1,200-patient study was futile. (BioWorld Today)